CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading compound profile…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Cannabinoids/(5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine

Endocannabinoids

(5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine

An <em>N</em>-acylethanolamine 20:5 that is the ethanolamide of (5<i>Z</i>,8<i>Z</i>,11<i>Z</i>,14<i>Z</i>17<i>Z</i>)-eicosapentaenoic acid.

Definition: CHEBI:71467 · Chemical Entities of Biological Interest · release 253

(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl ethanolamide(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl) ethanolamine(5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine(5Z,8Z,11Z,14Z17Z)-N-(2-hydroxyethyl)icosa-5,8,11,14,17-pentaenamideall-cis-eicosa-5,8,11,14,17-pentaenoyl ethanolamideall-cis-icosa-5,8,11,14,17-pentaenoyl ethanolamideAnandamide (20:5, n-3)eicosapentaenoyl ethanolamideEPEAicosapentaenoyl ethanolamideN-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)ethanolamineN-cis-5,8, 11,14,17-eicosapentaenoylethanolamine

6public articles

0registered condition areas

All documents →

Identity & provenance

Chemical identity

C22H35NO2 · molecular weight 345.527

CHEBI: CHEBI:71467↗HMDB: hmdb:HMDB0013649↗INCHI: InChI=1S/C22H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h3-4,6-7,9-10,12-13,15-16,24H,2,5,8,11,14,17-21H2,1H3,(H,23,25)/b4-3-,7-6-,10-9-,13-12-,16-15-↗INCHIKEY: OVKKNJPJQKTXIT-JLNKQSITSA-N↗LIPIDMAPS: lipidmaps:LMFA08040008↗PUBCHEM_CID: 5283450↗PUBMED: pubmed:20601112↗PUBMED: pubmed:20660502↗PUBMED: pubmed:21562563↗PUBMED: pubmed:23168911↗REAXYS: reaxys:7649107↗

Sources: ChEBI · 253 PubChem computed properties · pug-9896232d172275d5

0 referenced plant-occurrence records. They are identity candidates, not clinical evidence.

Research areas

Conditions found alongside this compound

Document links and organism occurrence are candidates, not proof of efficacy, safety or a treatment recommendation.

No published condition report is linked yet.

Linked local records

Medicines and registered studies

Links use source-reported active ingredients or study intervention names and remain candidates, not treatment claims.

Medicines with this active ingredient

No public medicine record matched.

Registered studies

0 exact source-intervention matches.

No registered study intervention matched.

Latest documents

Recent research

2025

The dietary ligands, omega-3 fatty acid endocannabinoids and short-chain fatty acids prevent cytokine-induced reduction of human hippocampal neurogenesis and alter the expression of genes involved in neuroinflammation and neuroplasticity.

Molecular Psychiatry · Free full text

2023

Endocannabinoid basis of personality-Insights from animal model of social behavior.

Frontiers in Pharmacology · Free full text

2023

N-eicosapentaenoyl-ethanolamine decreases the proliferation of psoriatic keratinocytes in a reconstructed psoriatic skin model.

Scientific Reports · Free full text

2023

Changes in plasma endocannabinoids concentrations correlate with 18F-FDG PET/MR uptake in brown adipocytes in humans.

Frontiers in Molecular Biosciences · Free full text

2020

Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats.

International Journal of Molecular Sciences · Free full text

2019

Fatty acids and selected endocannabinoids content in cerebrospinal fluids from patients with neuroinfections.

Metabolic Brain Disease · Free full text

Ontology definitions normalize terms; they do not establish medical claims.